NCD190.32

 

GAMMA GLUTAMYL TRANSFERASE

 

Effective Date of this Version

1/1/2003

 

Benefit Category

• Diagnostic Laboratory Tests

• Note: This may not be an exhaustive list of all applicable Medicare benefit categories for this item or service.

 

Item/Service Description

• Gamma Glutamyl Transferase (GGT) is an intracellular enzyme that appears in blood following leakage from cells.

o Renal tubules, liver, and pancreas contain high amounts, although the measurement of GGT in serum is almost always used for assessment of hepatobiliary function.

o Unlike other enzymes which are found in heart, skeletal muscle, and intestinal mucosa as well as liver, the appearance of an elevated level of GGT in serum is almost always the result of liver disease or injury.

o It is specifically useful to differentiate elevated alkaline phosphatase levels when the source of the alkaline phosphatase increase (bone, liver, or placenta) is unclear.

o The combination of high alkaline phosphatase and a normal GGT does not, however, rule out liver disease completely.

• As well as being a very specific marker of hepatobiliary function, GGT is also a very sensitive marker for hepatocellular damage.

o Abnormal concentrations typically appear before elevations of other liver enzymes or bilirubin are evident.

o Obstruction of the biliary tract, viral infection (e.g., hepatitis, mononucleosis), metastatic cancer, exposure to hepatotoxins (e.g., organic solvents, drugs, alcohol), and use of drugs that induce microsomal enzymes in the liver (e.g., cimetidine, barbiturates, phenytoin, and carbamazepine) all can cause a moderate to marked increase in GGT serum concentration.

o In addition, some drugs can cause or exacerbate liver dysfunction (e.g., atorvastatin, troglitazone, and others as noted in FDA Contraindications and Warnings.)

• GGT is useful for diagnosis of liver disease or injury, exclusion of hepatobiliary involvement related to other diseases, and patient management during the resolution of existing disease or following injury.

 

Indications and Limitations of Coverage

 

Indications

• To provide information about known or suspected hepatobiliary disease, for example:

o Following chronic alcohol or drug ingestion.

o Following exposure to hepatotoxins.

o When using medication known to have a potential for causing liver toxicity (e.g., following the drug manufacturer's recommendations).

o Following infection (e.g., viral hepatitis and other specific infections such as amoebiasis, tuberculosis, psittacosis, and similar infections).

• To assess liver injury/function following diagnosis of primary or secondary malignant neoplasms.

• To assess liver injury/function in a wide variety of disorders and diseases known to cause liver involvement (e.g., diabetes mellitus, malnutrition, disorders of iron and mineral metabolism, sarcoidosis, amyloidosis, lupus, and hypertension).

• To assess liver function related to gastrointestinal disease.

• To assess liver function related to pancreatic disease.

• To assess liver function in patients subsequent to liver transplantation.

• To differentiate between the different sources of elevated alkaline phosphatase activity.

 

Limitations

• When used to assess liver dysfunction secondary to existing non-hepatobiliary disease with no change in signs, symptoms, or treatment, it is generally NOT necessary to repeat a GGT determination after a normal result has been obtained unless new indications are present.

• If the GGT is the only "liver" enzyme abnormally high, it is generally NOT necessary to pursue further evaluation for liver disease for this specific indication.

• When used to determine if other abnormal enzyme tests reflect liver abnormality rather than other tissue, it generally is NOT necessary to repeat a GGT more than one time per week.

• Because of the extreme sensitivity of GGT as a marker for cytochrome oxidase induction or cell membrane permeability, it is generally NOT useful in monitoring patients with known liver disease.

• Note: Scroll down for links to the quarterly Covered Code Lists (including narrative).

 

Cross Reference

• Also see the Medicare Claims Processing Manual, Chapter 120, Clinical Laboratory Services Based on Negotiated Rulemaking.

 

Coverage Transmittal Link

• http://www.cms.gov/transmittals/downloads/R17NCD.pdf

 

Other

Covered Code Lists (including narrative)

• January 2013

October 2012

July 2012

April 2012

January 2012

October 2011

July 2011

April 2011

January 2011

October 2010

July 2010

April 2010

January 2010

October 2009

July 2009

April 2009

January 2009

October 2008

July 2008

April 2007

January 2007

 

Changes to Lab NCD Edit Software

• January 2012

October 2011

January 2011

October 2010

July 2010

October 2009

July 2009

January 2009

October 2008

July 2008

April 2007

January 2007

October 2006

July 2006

April 2006

January 2006

October 2005

July 2005

April 2005

January 2005

October 2004

July 2004

April 2004

January 2004

October 2003

July 2003

April 2003

 

Medicare NCD Link